Cargando…

Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series

OBJECTIVES: Anakinra is a selective IL-1 inhibitor, which has been used in the context of secondary haemophagocytic lymphohistiocytosis. Although usually given in the s.c. form, previous anecdotal reports have emphasized its utility when given i.v. Our aim is to report our experience on the benefici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clark, Kristina E N, Collas, Oliver, Lachmann, Helen, Singh, Animesh, Buckley, Jim, Bhagani, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Concise Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454860/ https://www.ncbi.nlm.nih.gov/pubmed/32964179 http://dx.doi.org/10.1093/rap/rkaa040

Ejemplares similares

Efficacy and safety of anakinra for undifferentiated autoinflammatory diseases in children: a retrospective case review
por: Garg, Suchika, et al.
Publicado: (2019)

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
por: Bozzi, Giorgio, et al.
Publicado: (2021)

Intravenous Immunoglobulin for the Rescue in Refractory Cutaneous Lupus
por: Singh, Harpreet, et al.
Publicado: (2020)

86. Intravenous anakinra treatment in a rare case of macrophage activation syndrome presenting as fulminant liver failure
por: Ghuman, Abeer, et al.
Publicado: (2018)

Anakinra treats fulminant myocarditis from Neisseria meningitidis septicaemia and haemophagocytic lymphohistiocytosis: a case report
por: Thomson, Ross J, et al.
Publicado: (2021)

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2022)

Intravenous administration of anakinra in children with macrophage activation syndrome
por: Phadke, Omkar, et al.
Publicado: (2021)

Intravenous anakinra for cytokine storm syndromes
por: Jamilloux, Yvan, et al.
Publicado: (2020)

COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics
por: Peet, Claire J, et al.
Publicado: (2021)

Treatment Experiences with Intravenous Immunoglobulins, Ixekizumab, Dupilumab, and Anakinra in Netherton Syndrome: A Case Series
por: Ragamin, Aviël, et al.
Publicado: (2023)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids
por: Calò Carducci, Francesca I., et al.
Publicado: (2020)

Pilot study evaluating intravenous amoxicillin-clavulanate as an alternative to piperacillin-tazobactam for general surgery patients
por: Drost, Sarah A., et al.
Publicado: (2023)

Intravenous anakinra for cytokine storm syndromes – Authors' reply
por: Mehta, Puja, et al.
Publicado: (2020)

Harvesting the low-hanging fruit? Comparative assessment of intravenous to oral route antimicrobial conversion policy implementation
por: Moehring, Rebekah W., et al.
Publicado: (2023)

Pustular Vasculitis: Different Names for Same Entity?
por: Kaushik, Shivani B., et al.
Publicado: (2019)

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
por: Cavalli, Giulio, et al.
Publicado: (2020)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
por: Yurttutan, Sadık, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Effectiveness and safety of anakinra in gouty arthritis: A case series and review of the literature
por: Jeria-Navarro, Sicylle, et al.
Publicado: (2023)

Human metapneumovirus in adults: a short case series
por: O’Gorman, C., et al.
Publicado: (2006)

Changes in intravenous and oral antimicrobial prescriptions during the coronavirus disease 2019 (COVID-19) pandemic: an experience at a tertiary-care center
por: Murakami, Shutaro, et al.
Publicado: (2022)

Paradoxical eczema in patients with psoriasis receiving biologics: a case series
por: Al‐Janabi, Ali, et al.
Publicado: (2022)

Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series
por: Bosma, A. L., et al.
Publicado: (2021)

Cutaneous Manifestations of COVID-19 Observed in Indian Patients: A Case Series
por: Jha, Niharika
Publicado: (2021)

Superimposed type 2 segmental atopic dermatitis: case series and review of the literature
por: Bar‐Ilan, Efrat, et al.
Publicado: (2022)

Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series
por: Malik, Mariam, et al.
Publicado: (2023)

Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease—an Auckland case series
por: Dick, Michael, et al.
Publicado: (2021)

Hyperinflammation, T cells, and endotoxemia
por: Inoue, Makoto, et al.
Publicado: (2015)

Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Empirical use of anakinra in AA amyloidosis of uncertain aetiology
por: Lane, T, et al.
Publicado: (2015)

High-dose intravenous vitamin C attenuates hyperinflammation in severe coronavirus disease 2019
por: Xia, Guozhi, et al.
Publicado: (2021)

Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye
por: Schultz, Clyde
Publicado: (2014)

Chemical Leucoderma of Oral and Labial Mucosal Surfaces from Neem [Azadirachta indica]. A Case Series
por: Jadhav, Prashant B.
Publicado: (2020)

Practical approaches for evaluating adrenal toxicity in nonclinical safety assessment
por: Inomata, Akira, et al.
Publicado: (2015)

Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children
por: Alolayan, Abdulaziz, et al.
Publicado: (2023)

Anakinra and hepatotoxicity in pediatric rheumatology: a case series
por: Martins, Frederico Rajão, et al.
Publicado: (2023)

Personalized management of essential thrombocythemia—application of recent evidence to clinical practice
por: Tefferi, A, et al.
Publicado: (2013)

Where are we with developing diagnostic criteria for skin diseases? Mapping the evidence in 2021
por: Luke, Jessie, et al.
Publicado: (2022)

Current evidence on the use of anakinra in COVID-19
por: Khani, Elnaz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mlk4vsofr96thnui0dbdf7von7